Ellagic Acid

Ellagic Acid

SCHEMBL1279897

O=c1oc2c(O)c(O)cc3c(=O)oc4c(O)c(O)cc1c4c23.OC[C@H]1OC(O)[C@H](O)[C@H]1O

nearest known ligand 0.62

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.62
HPGD P15428 3/20 0.62
APEX1 P27695 3/20 0.62
MEN1 O00255 3/20 0.62
KMT2A Q03164 3/20 0.62
HSD17B10 Q99714 2/20 0.62
MAPT P10636 2/20 0.62
RECQL P46063 2/20 0.62
BLM P54132 2/20 0.62
TDP1 Q9NUW8 2/20 0.62
AKR1B1 P15121 2/20 0.62
PKLR P30613 2/20 0.62
GALNT2 Q10471 2/20 0.62
GAA P10253 2/20 0.62
EPHX2 P34913 2/20 0.62
CA12 O43570 2/20 0.62
CA1 P00915 2/20 0.62
CA7 P43166 2/20 0.62
CA9 Q16790 2/20 0.62
CA13 Q8N1Q1 2/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ellagic Acid SCHEMBL1279583 0.99 KDM4E (0.60) KDM4EHPGDAPEX1MEN1KMT2A
SCHEMBL1699331 0.84 HSD17B10 (0.52) KDM4EHPGDAPEX1MEN1KMT2A
SCHEMBL29585250 0.83 SOST (0.53) KDM4EHPGDAPEX1MEN1KMT2A
SCHEMBL1279902 0.83 SOST (0.59) KDM4EHPGDAPEX1MEN1KMT2A
SCHEMBL1279584 0.82 SOST (0.60) KDM4EHPGDAPEX1MEN1KMT2A
SCHEMBL1444961 0.82 SOST (0.60) KDM4EHPGDAPEX1MEN1KMT2A
Ellagic Acid SCHEMBL8686557 0.81 KDM4E (0.96) KDM4EHPGDAPEX1MEN1KMT2A
Ellagic Acid SCHEMBL1645767 0.79 KDM4E (1.00) KDM4EHPGDAPEX1MEN1KMT2A
Ellagic Acid SCHEMBL29439360 0.79 KDM4E (1.00) KDM4EHPGDAPEX1MEN1KMT2A
Ellagic Acid SCHEMBL30475160 0.79 KDM4E (1.00) KDM4EHPGDAPEX1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9351492-B2 Anti-biofilm compositions and methods for using BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS (US) 2016-05-31 US claimed
US-20140271777-A1 ANTI-BIOFILM COMPOSITIONS AND METHODS FOR USING BOARD OF TRUSTEES UNIVERSITY OF ARKANSAS (US) 2014-09-18 US claimed
US-8741855-B2 Anti-biofilm compositions and methods for using THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS (US) 2014-06-03 US claimed
EP-2624702-A2 ANTI-BIOFILM COMPOSITIONS AND METHODS FOR USING The Board of Trustees of The University of Arkansas (US) 2013-08-14 EP claimed
US-20120088671-A1 ANTI-BIOFILM COMPOSITIONS AND METHODS FOR USING BOARD OF TRUSTEES UNIVERSITY OF ARKANSAS (US) 2012-04-12 US claimed
WO-2012048119-A2 ANTI-BIOFILM COMPOSITIONS AND METHODS FOR USING THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS (US) 2012-04-12 WO claimed
US-9351492-B2 Anti-biofilm compositions and methods for using BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS (US) 2016-05-31 US disclosed
EP-2624702-B1 ANTI-BIOFILM COMPOSITIONS AND METHODS FOR USING UNIV ARKANSAS (US) 2016-03-02 EP disclosed
US-20140271777-A1 ANTI-BIOFILM COMPOSITIONS AND METHODS FOR USING BOARD OF TRUSTEES UNIVERSITY OF ARKANSAS (US) 2014-09-18 US disclosed
US-8741855-B2 Anti-biofilm compositions and methods for using THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS (US) 2014-06-03 US disclosed
EP-2624702-A2 ANTI-BIOFILM COMPOSITIONS AND METHODS FOR USING The Board of Trustees of The University of Arkansas (US) 2013-08-14 EP disclosed
US-20120088671-A1 ANTI-BIOFILM COMPOSITIONS AND METHODS FOR USING BOARD OF TRUSTEES UNIVERSITY OF ARKANSAS (US) 2012-04-12 US disclosed
WO-2012048119-A2 ANTI-BIOFILM COMPOSITIONS AND METHODS FOR USING THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS (US) 2012-04-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140271777-A1 ANTI-BIOFILM COMPOSITIONS AND METHODS FOR USING TIMP3, MMP13, MMP8 KDM4E 1528/4885HPGD 1190/4885APEX1 646/4885
US-20120088671-A1 ANTI-BIOFILM COMPOSITIONS AND METHODS FOR USING TIMP3, MMP13, MMP8 KDM4E 1528/4885HPGD 1190/4885APEX1 646/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.